Immunotherapeutics
Author(s)
Bibliographic Information
Immunotherapeutics
（Advances in protein chemistry and structural biology, v. 129）
Academic Press, an imprint of Elsevier, 2022
Available at / 9 libraries
-
No Libraries matched.
- Remove all filters.
Note
Includes bibliographical references
Description and Table of Contents
Description
Immunotherapeutics, Volume 129 in the Advances in Protein Chemistry and Structural Biology series highlights new advances in the field, with this new volume presenting interesting chapters on a variety of topics, including Vaccines for the prophylaxis and treatment of HPV, Lung-targeted RNA-based therapeutics, Clostridium difficile: Current overview and future perspectives, Antivenoms for treatment of snake bites, Natural killer cell-based strategies for immunotherapy of cancer, Immunological insights of selectins in human disease mechanism, Current update, challenges, and future aspects of immunotherapeutics in non-small cell lung cancer, In silico interaction analysis of NEMO binding domain peptide on the NFkB protein, and much more.
Table of Contents
1. In silico tools and databases for designing cancer immunotherapy Anjali Dhall, Shipra Jain, Neelam Sharma, Leimarembi Devi Naorem, Dilraj Kaur, Sumeet Patiyal, and Gajendra P.S. Raghava2. Immunotherapeutic approaches for HPV-caused cervical cancerSeyed Amirreza Fatemi, Nadia Seifi, Shiva Rasekh, Sogand Amiri, Seyed Mohammad Iman Moezzi, Ashkan Bagheri, Shirin Fathi, and Manica Negahdaripour3. Natural killer cell-based strategies for immunotherapy of cancerOndrej Vanek, Barbora Kalouskova, Celeste Abreu, Shiva Nejadebrahim and Ondrej Skorepa4. Noncoding RNAs as novel immunotherapeutic tools against cancer Maninder Kaur, Bhavneet Kaur, Monidipa Konar, and Sadhna Sharma5. Immunological insights of selectins in human disease mechanism Chandrabose Selvaraj, Rajaram Abhirami, Rajendran Vijayakumar, Faiz Abdulaziz Alfaiz, and Sanjeev Kumar Singh6. CoVaccine HT (TM) adjuvant is superior to Freund's in eliciting ovine polyclonal antibodies against human tumor necrosis factor-alphaOwen R. Griffiths, John Landon, R. Keith Morris, Philip E. James, and Rachel A. Adams7. Clostridioides difficile: Current overview and future perspectives Joanna Giles and April Roberts8. A computational model revealing the immune-related hub genes and key pathways involved in rheumatoid arthritis (RA) Ambritha Balasundaram, S. Udhaya Kumar, and C. George Priya Doss9. Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach D. Thirumal Kumar, M.S. Shree Devi, S. Udhaya Kumar, Annie Sherlin, Aishwarya Mathew, M. Lakshmipriya, P. Sathiyarajeswaran, R. Gnanasambandan, R. Siva, R. Magesh, and C. George Priya Doss10. Immunotherapeutic interventions in Parkinson's disease: Focus on a-Synuclein Upasana Ganguly, Sukhpal Singh, Sasanka Chakrabarti, Adesh K. Saini, and Reena V. Saini11. Antivenom: An immunotherapy for the treatment of snakebite envenoming in sub-Saharan AfricaMender M. Mender, Fiona Bolton, Colin Berry, and Mark Young
by "Nielsen BookData"